Abstract

The antioxidant activity of drugs used in the treatment of diabetes has been proven to be a beneficial property in reducing diabetes-related complications. Properties of secondary metabolites of fungal endophytes Penicillium brevicaule alba CC200 and Aspergillus egypticus HT166S isolated from native medicinal plants as pancreatic α-amylase inhibitors, and their antioxidant activity were investigated. P. brevicaule alba CC200 and A. egypticus HT166S methanol fractions at 25 mg/ml concentration were found to have high inhibitory activity and IC₅₀ values were 0.49 and 0.68 mg/ml, respectively. Antioxidant activity was tested by 2,2-diphenyl-1-picrylhydrazine, hydrogen peroxide, and phospho molybdenum free radicals scavenging assays. Both endophytic strains in all tests exposed antioxidant activity. Still, the activity of A. egypticus HT166S extract was higher with IC₅₀ values 1.14, 0.46, 0.46 mg/ml and comparable to ascorbic acid efficiency with IC₅₀ values 0.91, 0.40, 0.40 mg/ml, correspondingly. The data obtained allowed us to consider that P. brevicaule alba CC200 and A. egypticus HT166S could be potential sources of complex drugs for type 2 diabetes.

中文翻译：

---

Penicillium brevicaule alba CC200 和 Aspergillus egypticus HT166S 的甲醇组分的抗糖尿病和抗氧化活性的比较评价

摘要

用于治疗糖尿病的药物的抗氧化活性已被证明是减少糖尿病相关并发症的有益特性。研究了从本地药用植物中分离的真菌内生菌Penicillium brevicaule alba CC200 和Aspergillus egypticus HT166S 的次级代谢产物的特性，作为胰腺 α-淀粉酶抑制剂，及其抗氧化活性。发现浓度为 25 mg/ml 的P. brevicaule alba CC200 和A. egypticus HT166S 甲醇级分具有高抑制活性和 IC ₅₀值分别为 0.49 和 0.68 mg/ml。通过 2,2-二苯基-1-苦基肼、过氧化氢和磷钼自由基清除试验测试了抗氧化活性。所有测试中的两种内生菌株都暴露了抗氧化活性。尽管如此， A.egypticus HT166S 提取物的活性更高，IC ₅₀值为 1.14、0.46、0.46 mg/ml，与抗坏血酸效率相当，IC ₅₀值为 0.91、0.40、0.40 mg/ml，相应地。获得的数据使我们能够考虑P. brevicaule alba CC200 和A. egypticus HT166S 可能是 2 型糖尿病复杂药物的潜在来源。